secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001628280-24-020466
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell reports Q1 net loss $60.7M; cash $526.3M; LYL797 data due this quarter
----------------------------------------------------------------------------

- Net loss $60.7M vs $67.0M YoY; non-GAAP net loss $37.5M vs $44.8M.
- Cash, equivalents and securities $526.3M; expected to fund operations into 2027.
- Initial Phase 1 data for LYL797 (ROR1 CAR T) expected this quarter from ≥20 patients.
- LYL845 (TIL) Phase 1 data expected H2 2024; LYL119 IND submission expected this quarter.
- R&D expenses $43.2M vs $44.6M; G&A $13.5M vs $19.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/lyel-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer